{"filing":{"accession_number":"0001193125-26-343469","cik":"0001678660","ticker":"PRLD","company_name":"Prelude Therapeutics Inc","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"prld-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-20260811.htm"},"events":[{"id":26890,"run_id":24458,"accession_number":"0001193125-26-343469","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $5.7 million, net loss of $13.9 million ($0.14 per share), R\u0026D and G\u0026A expenses, and cash position of $155.2 million. The filing includes audited financial statements (Statements of Operations and Balance Sheets) as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.","company_name":"Prelude Therapeutics Inc","ticker":"PRLD","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28182,"accession_number":"0001193125-26-343469","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $5.7 million, net loss of $13.9 million ($0.14 per share), R\u0026D and G\u0026A expenses, and cash position of $155.2 million. The filing includes audited financial statements (Statements of Operations and Balance Sheets) as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:01:52.152824+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28182,"accession_number":"0001193125-26-343469","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $5.7 million, net loss of $13.9 million ($0.14 per share), R\u0026D and G\u0026A expenses, and cash position of $155.2 million. The filing includes audited financial statements (Statements of Operations and Balance Sheets) as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:01:52.152824+00:00","company_name":"Prelude Therapeutics Inc","ticker":"PRLD","filing_date":"2026-08-11"}]}